"Following the gut The Anatara/Zoetis deal is a company maker"
Pitt Street Research Report
Melbourne, Mar 19, 2019 AEST (ABN Newswire) - Pitt Street Research has released its latest initiating research and valuation report on Anatara Lifesciences (
ASX:ANR) (ANR). The report provides a $1.34 per share base case and a $3.61 optimistic case using a probability-weighted DCF valuation approach.
Key Points
- Anatara is currently trading way below this valuation range
- Potential for Anatara to be re-rated by the market as GaRP progresses and as Zoetis gains regulatory approvals and launches Detach in North America, Europe and Asia.
- The opportunity for Detach is remarkable, given the size and scale of Zoetis' animal health portfolio
- Interest from one of the largest animal health companies worldwide reaffirms the credibility of the bromelain technology and reduces Anatara's cost burden, while providing a stream of cash flow to help the company move forward with its plans in human GI health
To view the research report, please visit:
http://abnnewswire.net/lnk/48047EVD
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
